{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"23.9","upperLimit":"33.9","value":"92"},{"groupId":"OG001","value":"41"}]}],"title":"ACR50"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"10.0","upperLimit":"17.6","value":"44"},{"groupId":"OG001","value":"21"}]}],"title":"ACR70"}],"denoms":[{"counts":[{"groupId":"OG000","value":"318"},{"groupId":"OG001","value":"157"}],"units":"Participants"}],"description":"ACR50 or ACR70 response was defined as a ≥ 50% or 70% improvement compared with baseline in both tender joint count (TJC) \\[68 joints\\] and swollen joint count (SJC) \\[66 joints\\] as well as a ≥ 50% or 70% improvement in three of five additional measurements: 1) Physician's Global Assessment of disease activity \\[visual analog scale: 0=no disease activity to 100=maximum disease activity\\]; 2) Patient's Global Assessment of Disease Activity \\[visual analog scale: 0=no disease activity to 100=maximum disease activity\\]; 3) Patient's Assessment of Pain \\[visual analog scale: 0=no pain to 100=unbearable pain\\]; 4) Health Assessment Questionnaire \\[20 questions, 8 components: dressing/grooming, arising, eating, walking, hygiene, reach, grip, and activities, 0=without difficulty to 3=unable to do\\] and 5) erythrocyte sedimentation rate.","groups":[{"description":"1000 mg rituximab intravenous initial treatment on day 1 and day 15 plus 10-25 mg/week methotrexate followed by re-treatment during weeks 24 -40 consisting of two additional doses of 1000 mg rituximab 14 days apart plus 10-25 mg/week methotrexate.","id":"OG000","title":"Arm A: Rituximab Retreatment"},{"description":"1000 mg rituximab initial treatment on day 1 and day 15 plus 10-25 mg/wk methotrexate followed by re-treatment during weeks 24 -40 consisting of two doses of placebo 14 days apart plus 10-25 mg/wk methotrexate.","id":"OG001","title":"Arm B: Placebo Retreatment"}],"paramType":"NUMBER","populationDescription":"Intent-to-treat population includes all participants randomized to Retreatment.","reportingStatus":"POSTED","timeFrame":"Baseline, Week 48","title":"Retreated Subjects With American College of Rheumatology 50% (ACR50) Response and American College of Rheumatology 70% (ACR70) Response at Week 48 Relative to Baseline","type":"SECONDARY","unitOfMeasure":"Participants"}